Search Results

Annovis Bio Inc. today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap.

Annovis Bio Inc. today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap.

Annovis Bio Inc. announced the filing of a provisional patent covering the manufacturing process of new solid forms of buntanetap.

Annovis Bio Inc announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.

Annovis Bio, Inc. announced that Maria Maccecchini, Founder, President, and CEO of Annovis, issued a letter to stockholders providing a review of Phase II/III data from its Alzheimer’s study and sharing next steps.

Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD), is pleased to announce that it has been selected to present the data from its latest Alzheimer’s study in an extended 45-minute session at the Alzheimer’s Association International Conference® 2024 (AAIC®).

Annovis Bio, Inc. announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases.

Annovis Bio, Inc., a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results.

Annovis Bio, Inc., a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson’s disease.

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer’s (AD) and Parkinson’s disease (PD), today announced the data from its Phase II/III Alzheimer study of buntanetap in mild to moderate AD patients.